DEA fee waiver
This article was originally published in The Tan Sheet
Executive Summary
Denying a registration waiver to distributors who handle controlled substances as well as List I chemicals would disproportionately raise fees by requiring them to file separate registrations, four trade organizations state in Jan. 17 comments to the Drug Enforcement Administration. The Consumer Healthcare Products Association, the Food Marketing Institute, the Healthcare Distribution Management Association and the National Association of Chain Drug Stores submitted joint comments addressing the possible removal of the List I registration waiver. "A single controlled substances distributor that is also a List I chemical handler would see a fee increase from $813 to $2,386 - nearly a three-fold increase - under this redundant fee scenario," they state. Maintaining two DEA registration numbers would also create "significant paperwork and operational burdens" for the agency and the industry. The DEA should retain the waiver for List I and controlled substances distributors, and provide information on the anticipated results of such fees, the organizations state...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.